Search

Your search keyword '"Shyr, Yu"' showing total 799 results

Search Constraints

Start Over You searched for: Author "Shyr, Yu" Remove constraint Author: "Shyr, Yu" Database Unpaywall Remove constraint Database: Unpaywall
799 results on '"Shyr, Yu"'

Search Results

2. Interoperability of phenome-wide multimorbidity patterns: a comparative study of two large-scale EHR systems

26. Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer

27. A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors

30. NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma

31. Longitudinal nucleocapsid antibody testing reveals undocumented SARS-CoV-2 infections in patients with lung cancer

33. A Specialized Epithelial Cell Type Regulating Mucosal Immunity and Driving Human Crohn’s Disease

34. Identification and Characterization of Avoidable Hospital Admissions in Patients With Lung Cancer

37. Abstract CT145: Olaparib +/- atezolizumab in patients with BRCA-mutated (BRCAmt) locally advanced unresectable or metastatic (advanced) breast cancer: an open-label, multicenter, randomized phase II trial

38. Supplementary Figure from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19

39. Data from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19

40. Data from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19

41. Supplementary Data from Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma

42. Data from Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma

43. Supplementary Figure from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19

44. Abstract 798: SeroNet Pooling Project of immunocompromised populations

45. Supplementary Data from Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma

46. Supplementary Table 1 from Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma

47. Data from Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma

48. Supplementary Table 1 from Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma

49. Data from ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer

50. Data from ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer

Catalog

Books, media, physical & digital resources